IPAB quashes revocation of Novartis patent for anti-cancer drug Ceritinib

Leave a Comment / News / By

[ad_1]


Natco filed a post-grant opposition against the patent on September 26, 2017, on grounds of obviousness and lack of inventive step.

[ad_2]

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *